Global Connected Drug Delivery Devices Market 2023

Description
The Connected Drug Delivery Devices Market is projected to grow from USD 646.3 million in 2022 to USD 3.54 billion by 2029. This growth is driven by the increasing prevalence of chronic diseases, rising geriatric population, and patient awareness of therapy adherence. Connected drug delivery devices are wireless and smart electronic devices that allow patients to self-administer therapy. They track dose delivery and provide instant feedback. The COVID-19 pandemic initially boosted the market as care shifted to home-based technologies, but the market is expected to maintain stable growth. Key drivers include chronic disease prevalence, patient connectivity, and engagement. Challenges include device cost and data privacy concerns. Despite challenges, the market is expected to expand due to chronic disease prevalence and growing awareness of therapy adherence.

Market Segmentation
The market is segmented based on various factors, including product, technology, end user, and geography.

Segmentation by Product
Connected Sensors - Connected Inhaler Sensors, Connectable Injection Sensors
Integrated Connected Devices - Connected Inhaler Devices, Connected Injection Devices

Segmentation by Technology
Bluetooth
Near-field communication (NFC)
Others

Segmentation by End User
Healthcare Providers
Homecare

Segmentation by Geography
North America - United States, Canada, Mexico
Europe - United Kingdom, Germany, France, Italy, Spain, and Rest of Europe
Asia-Pacific - China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific
Latin America - Brazil, Argentina, and Rest of Latin America
Middle East and Africa - GCC, South Africa, and Rest of Middle East and Africa

Integrated connected devices dominate the market, driven by technological advancements, increased adoption of connected inhaler devices, and product launches. Bluetooth technology holds the largest share among technology segments, thanks to its widespread availability in smartphones and ease of access. Bluetooth enables high-speed, low-energy communication between devices and operates in the 2.45 GHz frequency band. It supports up to 721 KBps and three voice channels, allowing medical devices to wirelessly communicate within a range of up to 30 feet (10 meters). This cost-effective technology is widely used in the industry.

The homecare segment is expected to dominate the market, driven by the increasing use and adoption of connected drug delivery devices in home settings. This segment will experience significant growth due to the rising cases of cardiovascular diseases (CVDs), diabetes, chronic obstructive pulmonary disease (COPD), and other chronic diseases that require proper health record maintenance. Innovations in connected drug delivery devices will further boost segment growth. The prevalence of diabetes and the growing geriatric population contribute to the demand for homecare solutions. Additionally, the global burden of cardiovascular diseases (CVDs) is increasing, leading to excess deaths in many regions. These factors drive the usage of connected drug delivery devices in homecare settings.

North America, particularly the United States, holds the largest market share due to its geographic location. The region also has a high prevalence of chronic diseases and a large target population. In the United States alone, approximately 25 million people suffer from asthma and over 15 million Americans are affected by COPD each year. Furthermore, Canada has a notable elderly population that is more susceptible to chronic diseases, leading to increased demand for connected drug delivery devices.

Competitive Landscape
The connected drug delivery devices market is fragmented, with key players utilizing strategic collaborations, acquisitions, and new product launches to remain competitive. Key companies profiled in this report are Propeller Health (ResMed Inc.), Findair Sp. z o.o., Bio Corp, Teva Pharmaceuticals Industries Ltd, Adherium Limited, West Pharmaceutical Services Inc., Aptar Pharma, Ypsomed AG, and Phillips-Medisize.

Recent Industry Developments
Jabil Healthcare, a division of Jabil Inc., introduced the Qfinity autoinjector platform in the United States in May 2022. This reusable drug delivery device is specifically designed for subcutaneous (SC) drug self-administration and is available in a connected option as well.

In February 2022, Aptar Pharma, a well-known global provider of drug delivery systems, launched the HeroTracker Sense in the United States. This innovative solution enhances a standard metered dose inhaler (pMDI) by transforming it into a smart connected healthcare device for digital respiratory health.